NCT06872294 Research of Predictive Factors of in Vitro Fertilization (IVF) Outcome AI-IVF Study
| NCT ID | NCT06872294 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia |
| Condition | Autoimmune Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-11-22 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2024-11-22 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Infertility is the failure to achieve a clinical pregnancy after 12 months or more of regular unprotected intercourse, while subfertility means a delay in achieving pregnancy. Several factors can contribute to these conditions, such as autoimmune diseases like systemic thyroid and celiac diseases, rheumatoid arthritis, systemic lupus erythematosus, and endometriosis. Some of them may overlap, sharing a common immunological milieu. In this scenario, medically ART can help women carry on pregnancies if they are in stable disease remission and receive adequate treatment. However, the number of oocytes that can be ovulated under stimulation is highly variable, so the outcome of any IVF is linked to many factors, not only biological but also connected to the mean success rate of the fertility center. For these reasons, the need to find methods for identifying the best gametes and embryos to guarantee a successful pregnancy is becoming pressing. AI can be essential to develop prediction models for pregnancy outcomes for patients undergoing ART treatments. AI currently represents a modern way to obtain algorithms from a set of observable data that could help clinical decisions
Eligibility Criteria
Inclusion Criteria: * Women with age below 43 years old * IVF cycle with fresh semen sample that could be used * progressive motile spermatozoa expected count of minimum 1 million following density gradient purification on the day of oocyte pick up Exclusion Criteria: * Women with uterine abnormalities * Women with chromosomal and genetic abnormalities * Positivity to serological test (HCV, HBV, HIV, VDRL-TPHA)
Contact & Investigator
Claudia Omes, PhD
PRINCIPAL INVESTIGATOR
Fondazione IRCCS Policlinico San Matteo di Pavia
Frequently Asked Questions
Who can join the NCT06872294 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 43 Years, studying Autoimmune Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06872294 currently recruiting?
Yes, NCT06872294 is actively recruiting participants. Contact the research team at c.omes@smatteo.pv.it for enrollment information.
Where is the NCT06872294 trial being conducted?
This trial is being conducted at Pavia, Italy.
Who is sponsoring the NCT06872294 clinical trial?
NCT06872294 is sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia. The principal investigator is Claudia Omes, PhD at Fondazione IRCCS Policlinico San Matteo di Pavia. The trial plans to enroll 200 participants.